Skip to content


Pediatric Rheumatology

Open Access

OR2-002 – The risk of FMF in MEFV heterozygotes

  • I Jéru1, 2, 3,
  • V Hentgen4,
  • E Cochet3,
  • P Duquesnoy1,
  • G Le Borgne1, 2,
  • E Grimprel2, 5,
  • K Stankovic Stojanovic6,
  • S Karabina1, 2,
  • G Grateau2, 6 and
  • S Amselem1, 2, 3
Pediatric Rheumatology201311(Suppl 1):A2

Published: 8 November 2013


Healthy IndividualGenetic CounsellingGenetic DiseasePopulation LevelStatistical Demonstration


Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder due to MEFV mutations and one of the most frequent Mediterranean genetic diseases. The observation of many heterozygous patients in whom a second mutated allele was excluded led to propose that heterozygosity could be causal; however, this might often be coincidental due to the very high rate of mutations in Mediterranean populations.


To better delineate the pathogenicity of heterozygosity in order to help genetic counselling and better manage the disease.


Complementary statistical approaches were used: estimation of FMF prevalence at population levels, genotype comparison in siblings from 63 familial forms, and genotype study in 557 patients from four Mediterranean populations.


At population level, we did not observe any contribution of heterozygosity to the disease prevalence. In affected siblings of patients carrying two MEFV mutations, 92% carry two mutated alleles whereas 4% are heterozygous with typical FMF diagnosis. We also demonstrated statistically that patients are more prone to be heterozygous than healthy individuals, as shown by the higher ratio heterozygous carriers/non carriers in patients (p<10-7 - p<0.003). The risk for heterozygotes to develop FMF was estimated between 2.1x10-3 and 5.8x10-3 and the relative risk, as compared to individuals carrying no MEFV mutation, between 6.3 and 8.1.


This is the first statistical demonstration that heterozygosity is not responsible for classical Mendelian FMF, but constitutes a susceptibility factor for clinically-similar complex conditions. We also provide a first estimate of the risk for heterozygotes to develop FMF.

Disclosure of interest

None declared.

Authors’ Affiliations

UMR_S933, INSERM, France
Université Pierre et Marie Curie-Paris6, France
Service de Génétique, APHP, Hôpital Trousseau, Paris, France
Centre de Référence des Maladies AutoInflammatoires, Centre Hospitalier de Versailles, Le Chesnay, France
Service de Pédiatrie Générale, APHP, Hôpital Trousseau, France
Service de Médecine Interne, APHP, Hôpital Tenon, Paris, France


© Jéru et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.